Menu
Not yet recruiting NCT05930353

Psychometric Validation of a French-language Version of the PERMA-Profiler: Tools for Assessing Multidimensional Subjective Well-being

Observational Psychiatric Disorder

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: COHORT.
Who it may be relevant to
Registry conditions: Psychiatric Disorder. Basic parameters: 18 years — 99 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
France
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Overview

The main objective of this study is to carry out the psychometric validation of the PERMA-Profiler in a population representative of the general French population and in comparison with the reference questionnaire The PERMA-Profiler.

Interventions

  • Other COHORT
    this evaluation includes a brief interview with perma profiler scale

Primary outcome measures

  • PERMA PROFILER French Version: diagnostic properties [Time frame: DAY 0]

Eligibility criteria

Inclusion criteria

  • Adult (≥18 years).
  • Person able to read and understand French
  • Person willing to participate in this study

Exclusion criteria

  • The person does not understand the French language
  • Person has a history of traumatic brain injury
  • The person refuses to participate in the study

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Observational model
Cohort

Study locations

France · 1 center
  • Chu de Nimes — Nîmes

Identifiers

NCT: NCT05930353 · LOCAL/2023/JJ-01

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗